Strategies for proprotein convertase subtilisin kexin 9 modulation: A perspective on recent patents

Expert Opinion on Therapeutic Patents

Volumn 20, Issue 11, 2010, Pages 1547-1571

  Abifadel, Marianne ^a,b   Pakradouni, Jihane ^b   Collin, Matthieu ^c   Samson Bouma, Marie Elisabeth ^a   Varret, Mathilde ^a   Rabès, Jean Pierre ^a,d,e   Boileau, Catherine ^a,d,e  

^a BICHAT HOSPITAL   (France)

^b SAINT JOSEPH UNIVERSITY   (Lebanon)

^c INSERM   (France)

^d HÔPITAL AMBROISE PARÉ   (France)

^e LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

antibody; familial hypercholesterolemia; patent; PCSK9; RNAi

Indexed keywords

AMG 145; ANTISENSE OLIGONUCLEOTIDE; ATORVASTATIN; BERBERINE; BMS 844421; CHENODEOXYCHOLIC ACID; COMPACTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PCSK 9; PLACEBO; POLYNUCLEOTIDE; PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9; REGN 727; SERINE PROTEINASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

BINDING AFFINITY; CATALYSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DOWN REGULATION; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; GENE CONTROL; GENE EXPRESSION; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; RNA INTERFERENCE; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

ANIMALS; CHOLESTEROL; CORONARY DISEASE; DRUG DELIVERY SYSTEMS; DRUG DESIGN; GENE EXPRESSION REGULATION; HUMANS; HYPERCHOLESTEROLEMIA; PATENTS AS TOPIC; RNA INTERFERENCE; SERINE ENDOPEPTIDASES;

EID: 77958462583     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.2010.518615     Document Type: Review

References (115)

1. Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003;34(2):154-6
2. Institut National de la Sante et de la Recherche Medicale. Mutations in the human PCSK9 gene associated to hypercholesterolemia. WO097047; 2004
3. Goldstein JL, Brown MS. Familial hypercholesterolemia: pathogenesis of a receptor disease. Johns Hopkins Med J 1978;143:8-16
4. Innerarity TL, Weisgraber KH, Arnold KS, et al. Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding. Proc Natl Acad Sci USA 1987;84(19):6919-23
5. Timms KM, Wagner S, Samuels ME, et al. A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum Genet 2004;114(4):349-53
6. Allard D, Amsellem S, Abifadel M, et al. Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia. Hum Mutat 2005;26(5):497
7. Bourbon M, Alves AC, Medeiros AM, et al. On behalf of the investigators of the Portuguese FH study. Familial hypercholesterolaemia in Portugal. Atherosclerosis 2007;196(2):633-42
8. Cameron J, Holla OL, Laerdahl JK, et al. Characterization of novel mutations in the catalytic domain of the PCSK9 gene. J Intern Med 2008;263(4):420-31
9. Homer VM, Marais AD, Charlton F, et al. Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa. Atherosclerosis 2007;196(2):659-66
10. Cameron J, Holla OL, Ranheim T, et al. Effect of mutations in the PCSK9 gene on the cell surface LDL receptors. Hum Mol Genet 2006;15(9):1551-8
11. Cohen J, Pertsemlidis A, Kotowski IK, et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005;37(2):161-5
12. Cohen J, Pertsemlidis A, Kotowski IK, et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005;37(2):161-5
13. Cohen JC, Boerwinkle E, Mosley TH Jr, et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006;354(12):1264-72
14. Kotowski IK, Pertsemlidis A, Luke A, et al. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Hum Genet 2006;78(3):410-22
15. Hooper AJ, Marais AD, Tanyanyiwa DM, et al. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis 2007;193(2):445-8
16. Humphries SE, Neely RD, Whittall RA, et al. Healthy individuals carrying the PCSK9 p.R46L variant and familial hypercholesterolemia patients carrying PCSK9 p.D374Y exhibit lower plasma concentrations ofPCSK9. Clin Chem 2009;55(12):2153-61
17. Benn M, Nordestgaard BG, Grande P, et al. PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. J Am Coll Cardiol 2010;55(25):2833-42
18. Abboud S, Karhunen PJ, Lutjohann D, et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9) gene is a risk factor of large-vessel atherosclerosis stroke. PLoS One 2007;2(10):e1043
19. Guella I, Asselta R, Ardissino D, et al. Effects of PCSK9 genetic variants on plasma LDL cholesterol levels and risk of premature myocardial infarction in the Italian population. J Lipid Res 2010; doi:10.1194/jlr.M010009
20. Brown MS, Goldstein JL. Biomedicine. Lowering LDL-not only how low, but how long? Science 2006;311(5768):1721-3
21. Herbert B, Patel D, Waddington SN, et al. Increased secretion of lipoproteins in transgenic mice expressing human D374Y PCSK9 under physiological genetic control. Arterioscler Thromb Vasc Biol 2010;30(7):1333-9
22. Abifadel M, Rabes JP, Devillers M, et al. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum Mutat 2009;30(4):520-9
23. Zhao Z, Tuakli-Wosornu Y, Lagace TA, et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 2006;79(3):514-23
24. Rashid S, Curtis DE, Garuti R, et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci USA 2005;102(15):5374-9
25. Millenium Pharmaceuticals, Inc. NARC-1, subtilase-like homologs. WO057081; 2001
26. Eli Lilly and Co. Novel secreted proteins and their uses. WO014358; 2002
27. Seidah NG, Benjannet S, Wickham L, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci USA 2003;100(3):928-33
28. Adaerata Limited partnership. Chimeric PCSK9 proteins, cells comprising same, and assay using same. WO128121; 2007
29. Benjannet S, Rhainds D, Hamelin J, et al. The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications. J Biol Chem 2006;281(41):30561- 72
30. Lagace TA, Curtis DE, Garuti R, et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest 2006;116(11):2995-3005
31. McNutt MC, Lagace TA, et al. Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells. J Biol Chem 2007;282(29):20799-803
32. Poirier S, Mayer G, Poupon V, et al. Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route. J Biol Chem 2009;284(42):28856-64
33. Zhang DW, Lagace TA, Garuti R, et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem 2007;282(25):18602-12
34. Zhang DW, Garuti R, Tang WJ, et al. Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor. Proc Natl Acad Sci USA 2008;105(35):13045-50
35. Cunningham D, Danley DE, Geoghegan KF, et al. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat Struct Mol Biol 2007;14(5):413-19
36. Piper DE, Jackson S, Liu Q, et al. The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol. Structure 2007;15(5):545-52
37. Fischer TS, Lo Surdo P, Pandit S, et al. Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation. J Biol Chem 2007;282(28):20502-12
38. Bottomley MJ, Cirillo A, Orsatti L, et al. Structural and biochemical characterization of the wild type PCSK9-EGF(AB) complex and natural familial hypercholesterolemia mutants. J Biol Chem 2009;284(2):1313-23
39. Irm LLC. Crystal structure of proprotein convertase 9 (PCSK9) and uses thereof. WO109871; 2008
40. Shan L, Pang L, Zhang R, et al. PCSK9 binds to multiple receptors and can be functionally inhibited by EGF-A peptide. Biochem Biophys Res Commun 2008;375(1):69-73
41. McNutt MC, Kwon HJ, Chen C, et al. Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells. J Biol Chem 2009;284(16):10561-70
42. Mayer G, Poirier S, Seidah NG. Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels. J Biol Chem 2008;283(46):31791-801
43. Maxwell KN, Soccio RE, Duncan EM, et al. Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice. J Lipid Res 2003;44(11):2109-19
44. Dubuc G, Chamberland A, Wassef H, et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2004;24(8):1454-9
45. Li H, Dong B, Park SW, et al. Hepatocyte nuclear factor 1 alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. J Biol Chem 2009;284(42):28885-95
46. Cameron J, Ranheim T, Kulseth MA, et al. Berberine decreases PCSK9 expression in HepG2 cells. Atherosclerosis 2008;201(2):266-73
47. Persson L, Galman C, Angelin B, et al. Importance of proprotein convertase subtilisin/kexin type 9 in the hormonal and dietary regulation of rat liver low-density lipoprotein receptors. Endocrinology 2009;150(3):1140-6
48. Langhi C, Le May C, Kourimate S, et al. Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes. FEBS Lett 2008;582(6):949-55
49. Schmidt RJ, Ficorilli JV, Zhang Y, et al. A 15-ketosterol is a liver X receptor ligand that suppresses sterol-responsive element binding protein-2 activity. J Lipid Res 2006;47(5):1037-44
50. Bell TA III, Brown JM, Graham MJ, et al. Liver-specific inhibition of acyl-coenzyme a: cholesterol acyltransferase 2 with antisense oligonucleotides limits atherosclerosis development in apolipoprotein B100-only low-density lipoprotein receptor-/-mice. Arterioscler Thromb Vasc Biol 2006;26(8):1814-20
51. Graham MJ, Lemonidis KM, Whipple CP, et al. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J Lipid Res 2007;48(4):763-7
52. Isis Pharmaceuticals, Inc. Compounds and methods for modulatin expression of PCSK9. WO143315; 2007
53. Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia. WO066776; 2008
54. Yu RZ, Geary RS, Leeds JM, et al. Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-ras mRNA in mouse and monkey. J Pharm Sci 2001;90(2)182-93
55. Yu RZ, Geary RS, Monteith DK, et al. Tissue disposition of 2'-O-(2-methoxy-) ethyl modified antisense oligonucleotides in monkeys. J Pharm Sci 2004;93(1):48-59
56. Greeve JI, Altkemper J, Dieterich H, et al. Apolipoprotein B mRNA editing in 12 different mammalian species: hepatic expression is reflected in low concentrations of apoB-containing plasma lipoproteins. J Lipid Res 1993;34:1367-83
57. Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia. WO148605; 2009
58. Frank-Kamenetsky M, Grefhorst A, Anderson NN, et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci USA 2008;105(33):11915-20
59. Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the PCSK9 gene. WO134161; 2007
60. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285(13):1711-18
61. Alnylam Pharmaceuticals, Inc. Optimized methods for delivery of dsRNA targeting the PCSK9 gene. WO134487; 2009
62. Alnylam Pharmaceuticals, Inc. Phosphorothioate oligonucleotides non-nucleosidic phosphorothiotes as delivery agents for iRNA agents. WO006237; 2010
63. Gupta N, Fisker N, Asselin MC, et al. A locked nucleic acid antisens oligonucleotide (LNA) silences PCSk9 and enhances LDLR expression in vitro and in vivo. PLoS One 2010;5(5):e10682
64. Zaid A, Roubtova A, Essalmani R, et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9): Hepatocye-specific low density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology 2008;48:646-54
65. Elmen J, Lindow M, Silahtaroglu A, et al. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res 2008;36:1153-62
66. Elmen J, Lindow M, Schutz S, et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008;452:896-99
67. Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010;327:198-201
68. Stenvang J, Silahtaroglu AN, Lindow M, et al. The utility of LNA in microRNA-based cancer diagnostics and therapeutics. Semin Cancer Biol 2008;18(2):89-102
69. Sapra P, Wang M, Bandaru R, et al. Down-modulation of survivin expression and inhibition of tumor growth in vivo by EZN-3042, a locked nucleic acid antisense oligonucleotide. Nucleosides Nucleotides Nucleic Acids 2010;29(2):97-112
70. Sirna Therapeutics, Inc. RNA interference mediated inhibition of proprotein convertases subtilisin kexin 9 (PCSK9) gene expression using short interfering nucleic acid (SINA). WO011431; 2008
71. Nastech Pharmaceutical Co., Inc. Nucleic acid compounds for inhibiting PCSK9 gene expression and uses thereof. WO109472; 2008
72. Santaris Pharma A/S. Pharmaceutical composition comprising anti PCSK9 oligomers. WO127680; 2009
73. Chan JC, Piper DE, Cao Q, et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci USA 2009;106(24):9820-5
74. Amgen, Inc. Antigen binding proteins to proprotein convertases subtilisin kexin type 9 (PCSK9). WO026558; 2009
75. Amgen, Inc. Neutralizing proprotein convertases subtilisin kexin 9 (PCSK9) variants and uses thereof. WO131740; 2009
76. Ni YG, Condra JH, Orsatti L, et al. A proprotein convertase subtilisin/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake. J Biol Chem 2010;285(17):12882-91
77. Regeneron Pharmaceuticals, Inc. High affinity human antibodies to PCSK9. WO077854; 2010
78. Labonte P, Begley S, Guevin C, et al. PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression. Hepatology 2009;50(1):17-24
79. Poirier S, Mayer G, Benjannet S, et al. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem 2008;283(4):2363-72
80. Jonas MC, Costantini C, Puglielli L. PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1. EMBO Rep 2008;9(9):916-22
81. Liu M, Wu G, Baysarowich J, et al. PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain. J Lipid Res 2010;51:2611-8
82. Shibata N, Ohnuma T, Higashi S, et al. No genetic association between PCSK9 polymorphisms and Alzheimer's disease and plasma cholesterol level in Japanese patients. Psychiatr Genet 2005;15(4):239
83. Langhi C, Le May C, Gmyr V, et al. PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion. Biochem Biophys Res Commun 2009;390(4):1288-93
84. Mbikay M, Sirois F, Mayne J, et al. PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities. FEBS Lett 2010;584(4):701-6
85. Regeneron Pharmaceuticals, Inc. 2010 PR Newswire. Available from: http://www.regeneron.com/pipeline.html
86. Careskey HE, Davis RA, Alborn WE, et al. Atorvastatin increases human serum levels of proprotein convertase subtilisin kexin type 9 (PCSK9). J Lipid Res 2008;49(2):394-8
87. Welder G, Zineh I, Pacanowski MA, et al. High dose atorvastatin causes a rapid, sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J Lipid Res 2010;51:2714-21
88. Fasano T, Cefalu AB, Di Leo E, et al. A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol. Arterioscler Thromb Vasc Biol 2007;27(3):677-81
89. Merck Sharp & Dohme Corp. PCSK9 Immunoassay. WO068526; 2010
90. Alnylam Pharmaceuticals, Inc. Processes for preparing lipids. WO048536; 2010
91. Alnylam Pharmaceuticals, Inc. Lipids and compositions for the delivery of therapeutics. WO054384; 2010
92. Carolus Therapeutics, Inc. Methods of treating cardiovascular disorders. WO056910; 2010
93. Intradigm Corp. Copositions comprising human PCSK9 and apolipoproteinB siRNA and methods of use. WO114475; 2009
94. Isis Pharmaceuticals, Inc. Compounds and methods for modulating the GCCR WO134014; 2007
95. Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression ofSGLT2. WO143316; 2007
96. Sanofi-Aventis. Use of substituted pyridinone carboxylic acid derivates for producing pharmaceuticals for the treatment of dyslipidemia. WO000401; 2010
97. Santaris Pharmaceuticals A/S. RNA antagonist compounds for the modulation of PCSK9. WO043753; 2008
98. Lambert G. Charlton F, Rye KA, et al. Molecular basis of PCSK9 function. Atherosclerosis 2009;203(1):1-7
99. Merck and Co., Inc. Antagonists of PCSK9. WO057457, 057458,057459 and 063382; 2008
100. Merck and Co., Inc. Antagonists of PCSK9. WO133647; 2008
101. Merck Sharp and Dohme Corp. 1B20 PCSK9 antagonists. WO100318; 2009
102. Merck Sharp and Dohme Corp. and Instituto di recherche di Biologia Molecolare SPA.1D05 PCSK9 antagonists. WO100297; 2009
103. Novartis AG. Molecules and methods for modulating PCSK9. WO125623; 2008
104. Rinat Neuroscience Corp. Pfizer, Inc. PCSK9 antagonists. WO029513; 2010
105. Schering Corp. Anti-PCSK9 and methods for treating lipid and cholesterol disorders. WO055783; 2009
106. Seidah NG. PCSK9 as a therapeutic target of dyslipidemia. Expert Opin Ther Targets 2009;13(1):19-28
107. Schering Corp. EGF-A domain-mediated modulation of PCSK9. WO143367; 2009
108. Hericks JA. Targeting PCSK9 for the treatment of hypercholesterolemia. Curr Opin Investig Drug 2009;10(9):938-46
109. Affiris AG. Vaccine. WO057242; 2010
110. Bristol-Myers Squibb Co. Polynucleotides encoding novel PCSK9 variants. WO105797; 2008
111. Institut de recherches cliniques de Montreal. PCSK9 inhibitors and methods of use thereof. WO143633; 2009
112. Merck and Co., Inc. Method for detecting autoprocessed, secreted PCSK9. WO118386; 2008
113. Odyssey Thera, Inc. High-content and high throughput assays for identification of lipid regulating pathways, and novel therapeutic agents for lipid disorders. WO111073; 2009
114. Partnership and Corp. Technology transfer. Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of muscle relaxation. WO071448; 2007
115. Kwon HJ, Lagace TA, McNutt MC, et al. Molecular basis for LDL receptor recognition by PCSK9. Proc Natl Acad Sci USA 2008;105(6):1820-25